-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cognitive impairment is common in Parkinson's disease (PD) and is a leading cause of disability and reduced quality of life
.
Mild cognitive impairment (PD-MCI) is already present in 25% to 30% of newly diagnosed
Quality of life diagnosis
Cognitive impairment in PD is heterogeneous, with multiple domains affected and with great variability in onset and progression
.
It is increasingly recognized that concurrent cholinergic dysfunction is a major factor in the pathophysiology of cognitive impairment in PD
The four major cholinergic systems of the human brain are the basal forebrain (BF) cortical flap projection system, the cholinergic outflow from the tentorial-lateral capsule complex (PPN/LDTC), and the medial vestibular nucleus (MVN) projections to the cerebellum cholinergic neurons, and striatal cholinergic interneurons
.
Previous in vivo neuroimaging assessment of cholinergic innervation using acetylcholinesterase positron emission tomography (PET) indicated that PD is predominantly posterior cholinergic innervation and that cholinergic degeneration is more severe in PDD
.
There is also evidence that the cholinergic system is a major driver of cognitive impairment in PD even in the absence of dementia
Although cholinergic innervation has been shown in cognitively impaired PD patients, little is known about changes in cholinergic innervation early in the disease and before cognitive changes occur
.
Elucidating the relationship between cognitive impairment and cholinergic integrity in the early stages of disease may provide new clues that inform new treatment strategies
Hereby, Sygrid van der Zee, PhD, PhD, of the University of Groningen, The Netherlands, describe the cholinergic innervation status of newly diagnosed, medication-naive PD patients with or without cognitive impairment
.
They compared acetylcholine transporter (VAChT) [18F]fluoroethoxybenzovesamicol-([18F]FEOBV) PET imaging between new patients (with or without MCI) and healthy controls (HCs)
Compared with the control group, both the PD-NC group and the PD-MCI group showed significant cortical cholinergic innervation (P<0.
05), mainly in the posterior cortical area
In PD-NC, higher-than-normal levels of binding were most prominent in cortical and subcortical regions, including the cerebellum, cingulate cortex, Putuomen, rectal gyrus, hippocampus, and amygdala
.
The significance of this study lies in the discovery that alterations in cholinergic innervation are already present in neonatal PD patients
.
Posterior cortical cholinergic loss in all patients was independent of cognitive status
Alterations in cholinergic innervation are already present in neonatal PD patients
.
Original source:
[Zee S, Kanel P, Gerritsen MJJ, et al.
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and without Cognitive Impairment.
Movement Disorders.
Published online January 17, 2022:mds.
28913.
doi:10.
1002/mds.
28913] (https://doi.
org/10.
1002/mds.
28913)
Movement Disorders.
Leave a Comment
